Northeastern University

Nanoformulated PARP inhibitors for treatment of ovarian & breast cancers

Merline Senat with Dr. Srinivas Sridhar (NU)

Within Dr. Srinivas Sridhar’s lab at Northeastern University, I am studying nanoparticle delivery for potent PARP inhibitors as a treatment for ovarian and breast cancers. My focus will be the formulation of these nanoparticles to allow for increased efficacy and sustained release of PARP inhibitors like Talazoparib. Some of the techniques that I will be learning in order to study this effectively include cell culture and high performance liquid chromatography (HPLC).